Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Appliance of science

- PMLiVE

AstraZeneca’s Voydeya granted FDA approval for rare blood disease PNH

Up to 20% of patients treated with C5 inhibitors experience clinically significant extravascular haemolysis

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

Gilead gains rights to Xilio’s early-stage solid tumour candidate in deal worth up to $647.5m

XTX301 is currently being evaluated in a phase 1 trial in patients with advanced solid tumours

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

Single genetic test could replace current standard for diagnosing rare developmental disorders

The single genetic test could potentially replace the current standard and reduce costs for the NHS

- PMLiVE

Enhancing collaborative decision-making for patients with MS

Optimising MS care and patient outcomes through advancing shared decision-making

- PMLiVE

Clinical Trial Protocol Conceptualization: A Customer Story

To set their Phase II clinical trial of a novel anti-cancer compound up for success, our client sought early multidisciplinary insights on current unmet needs, as well as feedback on their preclinical...

Impetus Digital

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Indegene announces acquisition of Trilogy Writing & Consulting

The deal is aimed at increasing Indegene’s clinical and regulatory writing expertise for global market authorisation applications

- PMLiVE

PMLiVE’s T40 – open for submissions!

Healthcare agencies can submit their entries free of charge with a deadline of 30 April

- PMLiVE

FDA grants Invivyd’s Pemgarda emergency use authorisation for COVID-19 prevention

The long-acting monoclonal antibody is authorised for use in adults and adolescents

- PMLiVE

Teva UK and Closed Loop Medicine partner to advance development of personalised medicines

The collaboration will utilise Closed Loop Medicine’s software as a medical device technology platform

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links